Shaping the Future of Precision Oncology in Malaysia

13 October 2026 | 3:00 PM | Prince Court Medical Centre (PCMC), Kuala Lumpur

Join leading voices from across Malaysia’s healthcare and oncology community for an afternoon exploring how precision oncology can move from vision to clinical impact.

Hear perspectives from IHH, the Ministry of Health, SOPHiA GENETICS and leading clinicians on the evolution of precision oncology in Malaysia — from genomic insights and AI-powered innovation to real-world clinical practice.

A Milestone for Precision Oncology

A key highlight of the afternoon will be the Memorandum of Understanding signing between Premier Integrated Labs (PIL) and SOPHiA GENETICS, marking a shared commitment to advancing precision medicine and strengthening Malaysia’s precision oncology ecosystem.

The programme will also feature clinical cases, expert perspectives and opportunities to connect with colleagues shaping the future of cancer care.

Programme

Register your Interest

We would be delighted to have you join us for this important milestone in Malaysia’s precision oncology journey.

El próximo 15 de octubre, en las instalaciones de INMEGEN, se llevará a cabo el GENOMiCS INSIGHTS Day México, un encuentro que reunirá a líderes clínicos, investigadores y especialistas en genómica para compartir experiencias y discutir el papel creciente de la medicina de precisión en la atención de pacientes oncológicos.

Durante la jornada se abordarán temas clave como los avances en programas de prevención y vigilancia genómica, la evolución del perfilamiento molecular desde tejido hasta biopsia líquida, y la implementación de programas de secuenciación a gran escala en instituciones de referencia internacionales. Asimismo, se presentarán experiencias regionales sobre el uso de la biopsia líquida para apoyar la toma de decisiones terapéuticas en cáncer y casos reales de adopción de tecnologías genómicas en la práctica clínica.

El evento contará con ponentes de reconocidas instituciones de México, Estados Unidos y Brasil, quienes compartirán perspectivas clínicas, operativas y científicas sobre la integración de la genómica en los sistemas de salud. La jornada finalizará con una mesa redonda y un espacio de networking, promoviendo el intercambio de conocimientos y la colaboración entre los profesionales de la región.

What: SOPHiA GENETICS exclusive networking event

Date: 15 de octobre

Time: 8h:30-13h:30

Where: INMEGEN

Agenda

Why Attend?

Descubra SOPHiA DDM™: una plataforma compatible con múltiples tecnologías, con infinitas posibilidades

Conozca cómo SOPHiA DDM™ permite realizar análisis precisos en diversas áreas de la medicina, desde oncología hasta enfermedades raras.

Aborde los desafíos actuales de la práctica clínica y la investigación

Participe en una conversación sobre el futuro de las instituciones de salud e investigación y descubra cómo aprovechar el potencial de los datos de secuenciación de nueva generación (NGS) para generar resultados rápidos, sólidos y accionables que faciliten una toma de decisiones informada.

Conecte con líderes de opinión y expertos del sector

Interactúe con colegas, investigadores y usuarios de la plataforma SOPHiA DDM™ en un espacio diseñado para el intercambio de conocimientos, experiencias y oportunidades de colaboración científica.

Large hospitals face a widening gap: guidelines are moving faster than most labs can validate against. And legacy PCR- and FISH-based workflows, however reliable, weren't built to scale to that pace. Prof. Klaus Schmetterer, Head of the Molecular Diagnostics Department, and his team at the Medical University of Vienna, Austria, one of Europe's largest tertiary care centers, are closing that gap.

In this session, Prof. Schmetterer shows how his team unlocked roughly 12 times more genomic coverage, at a comparable cost, without slowing down the turnaround clinicians rely on for treatment decisions. The shift: replacing a patchwork of single-gene and translocation assays with one integrated DNA/RNA NGS workflow, covering 500+ genes and 250+ translocations across both myeloid and lymphoid disease in a single run, powered by automated library preparation and the SOPHiA DDM™ platform's AI-driven variant analysis.

At the conclusion of this session, participants will be able to:

• Examine a practical model for scaling genomic testing in hematological malignancies through a single, comprehensive NGS application.
• Compare the operational and financial trade-offs of a consolidated workflow against running multiple fragmented assays, without added budget, headcount, or risk.
• Recognize how structured documentation support can help laboratory teams meet the EU's IVDR requirements while easing the workload that comes with it.

Presenter

Prof. Klaus Schmetterer, MD, PhD, heads the Cytogenetics Diagnostics section and the Molecular Biology in Hemato-Oncology Diagnostics section within the Department of Laboratory Medicine at the Medical University of Vienna (AKH Wien, Austria), roles he holds since 2022 and 2025 respectively. He also holds a tenure-track position at the university since 2021.

His path into hemato-oncology diagnostics began in immunology: he completed his Master's and PhD research in the laboratory of Winfried Pickl, MD, at the Institute of Immunology, Medical University of Vienna, earning his MD in 2010 and his PhD in Molecular Biology in 2011. He joined the Department of Laboratory Medicine in 2012 for his residency and completed it in 2018 as a board-certified specialist in Laboratory Medicine.

Join SOPHiA GENETICS at SFMPP 2026 in Paris, France! Come meet our team of experts at Booth #16. We are looking forward to discussing how we support laboratories and healthcare institutions with scalable, data-driven solutions. 

Stay tuned for information and session updates!

We are excited to attend SITC EU 2026 in Lausanne and connect with the European immunotherapy community to exchange insights on the latest advances in innovative therapies.

Join our BioPharma team to discover how AI-powered technology and diagnostics are helping advance precision oncology.

From genomic innovation to real-world implementation: exploring the future of liquid biopsy and precision oncology across the Middle East.

The conversation around precision medicine is rapidly evolving. In this on-demand session, leading oncology experts, healthcare decision-makers, pharmaceutical partners, policy representatives, and key opinion leaders come together to explore how liquid biopsy is transforming cancer care delivery and genomic testing strategies across the region.

Watch the full recording to hear expert perspectives, real-world experiences, and practical insights from leading institutions.

What You'll Discover

This high-level discussion explores the evolving role of liquid biopsy in precision oncology and the opportunities to bring advanced genomic testing closer to patients.

Decentralizing precision oncology
Learn how Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS collaborated to decentralize MSK’s renowned genomic assay, MSK-ACCESS™, powered with SOPHiA DDM™ for liquid biopsy applications.

From innovation to implementation
Hear real-world perspectives on implementing advanced genomic testing and scaling precision oncology solutions in clinical practice.

Regional insights from the Middle East
Discover how healthcare leaders in the region are approaching innovation, scalability, and the integration of genomic testing into cancer care.

The evolving role of liquid biopsy
Explore how liquid biopsy can contribute to more accessible and actionable genomic testing strategies and support the continued evolution of precision medicine.

Watch the Expert Discussion

Featuring perspectives from leading oncology, genomics, and precision medicine experts from Memorial Sloan Kettering Cancer Center, M42, and SOPHiA GENETICS.

We are delighted to participate in the ESMO AI & Digital Oncology Congress 2026, where you can meet with our Multimodal and BioPharma teams for three exciting days of innovation, networking, and insights into AI-powered solutions and breakthroughs to transform precision oncology.

Join us at booth #11 to:

• Explore how the SOPHiA DDM™ Platform transforms complex multimodal oncology data into actionable insights with AI-powered analytics
• Empower more confident decision-making with SOPHiA DDM™ Digital Twins by comparing similar patient profiles and simulating potential response outcomes
• Harness the global collective intelligence of our network to uncover valuable insights and advance precision oncology through data-driven innovation

SOPHiA GENETICS is at the 17th Annual Meeting of the Cancer Genomics Consortium. Find us at Booth #29 to see how the SOPHiA DDM™ Platform is helping laboratories move from fragmented workflows to AI-driven, integrated, end-to-end solutions, able to generate actionable, evidence-based insights at scale.

Discover a platform built for the complexity of cancer genomics, across solid tumors and hematologic malignancies, driven by its global community and trusted by 990+ institutions across 75 countries.

Drop by our booth for an in-depth demo of our end-to-end applications:

Booth #29 hours:

• Sun Aug 2, 3:15 PM–8:00 PM
• Mon Aug 3, 8:00 AM–6:30 PM
• Tues Aug 4, 8:00 AM–5:30 PM
• Wed Aug 5, 8:00 AM–11:15 AM 

Learn more:

• See MSK-IMPACT® Flex powered with SOPHiA DDM™ in action, comprehensive genomic profiling that spans DNA and RNA capture, as well as lpWGS
• Explore our SOPHiA DDM™ for Blood Cancers, built to help labs future-proof their workflows from detection through MRD (minimal residual disease) monitoring
• Learn how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) is decentralizing world-class genomic capabilities for clinical researchers beyond flagship centers
• Get a personalized demo from our oncology and genomics specialists

Don't miss: 🎤 Science Café Presentation,  Lizmery Ferguson Schires | Royal Sonesta Houston Galleria

Whether you're running a high-volume solid tumor program or building out comprehensive hemato-oncology capabilities, our team can show you how SOPHiA DDM™ streamlines the entire process, from concept to implementation.

Book 15 minutes with our team now or simply stop by our booth. See you in Houston.

One workflow, entirely in-house.

Most lab leaders arrive at ADLM with the same question: how do we bring NGS in-house, or scale what we already run, without adding headcount, cost, or turnaround time?

At Booth #1172, the AVITI24 system and the SOPHiA DDM™ Platform’s AI-powered analysis run as one connected workflow. Your lab sequences and interprets its own data, and your data stays in-house.

780+ institutions run SOPHiA DDM™ today
70+ countries, standardizing and scaling NGS workflows

Stop by Booth #1172, wherever your lab is.
Tell us where you are, and we’ll tailor the conversation.

Booth #1172 hours:
Tue Jul 28, 9:30 AM–5:00 PM
Wed Jul 29, 9:30 AM–5:00 PM
Thu Jul 30, 9:30 AM–12:00 PM

Launching an NGS program

See how to stand up sequencing and analysis together, without building a bioinformatics team from scratch.

Running an established program

See where SOPHiA DDM™ removes the bottlenecks you already feel: variant interpretation time, workflow standardization, and QC overhead.

Weighing in-house economics

Walk through the cost and turnaround math labs are using to build the business case for in-house testing.

Whether you’re evaluating NGS solutions, expanding your test menu, or exploring how AI can strengthen your genomic pipeline, our teams are ready to talk.

Book 15 minutes with our team now, or simply stop by and say hello. See you in Anaheim.

Join SOPHiA GENETICS™ and ARC Regulatory for an exclusive Industry Reception bringing together precision medicine and pharma leaders in Boston on July 21^st.

Following our recently announced Master Collaboration Agreement, this event will spotlight our integrated solution for pharma companies across the clinical development lifecycle in Europe, combining ARC's IVDR regulatory expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record.

You’ll hear directly from both teams about key milestones, including the co-development of a Clinical Trial Assay (CTA) designed to accelerate patient recruitment in European clinical trials.

Accelerate with Impact: Expanding Patient Access to Precision Medicine Across the EU

The programme will be followed by a networking reception, offering a unique opportunity to connect with peers and leaders shaping the future of precision medicine.

Reserve your spot today!